Agios Pharmaceuticals, INC 8-K filings

Agios Pharmaceuticals reported strong second quarter 2026 results, with mitapivat revenues reaching $44.7 million and significant pipeline advancements.

Agios Pharmaceuticals stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing available shares and authorizing incentive stock options.

Agios Pharmaceuticals announced first quarter 2026 financial results, highlighting strong net revenue growth for mitapivat and progress in its drug pipeline.

Agios Pharmaceuticals announced strong fourth-quarter and full-year 2025 financial results, highlighted by the U.S. launch of AQVESME and progress in its sickle cell disease programs.

Agios Pharmaceuticals announced its 2026 strategic priorities and key milestones, including the U.S. commercial launch of AQVESME for thalassemia and pipeline advancements.

Agios Pharmaceuticals announced its third quarter 2025 financial results, reporting $12.9 million in PYRUKYND net revenues and providing updates on key clinical and regulatory milestones for its rare disease pipeline.

Agios Pharmaceuticals addresses recent PYRUKYND safety concerns from an analyst report, affirming the drug's benefit-risk profile, while simultaneously announcing regulatory approval in Saudi Arabia for thalassemia.

Agios Pharmaceuticals announced second quarter 2025 financial results, highlighting increased PYRUKYND net revenues and significant pipeline progress, including an upcoming FDA decision for thalassemia and on-track Phase 3 sickle cell disease trial results.

Agios Pharmaceuticals, Inc. announced the election of Dr. Jay Backstrom to its Board of Directors, effective July 8, 2025, enhancing its scientific and technological oversight.

Agios Pharmaceuticals, Inc. announced that its stockholders approved the 2023 Stock Incentive Plan amendment, elected two Class III directors, and ratified executive compensation and the independent auditor at its 2025 Annual Meeting.

Agios Pharmaceuticals announced its first quarter 2025 financial results, highlighting regulatory progress for PYRUKYND in thalassemia and the advancement of its sickle cell disease program.

Agios Pharmaceuticals announces Q4 and full-year 2024 financial results, highlighted by PYRUKYND revenue growth and progress in regulatory filings and clinical trials.

David P. Schenkein, M.D., resigned from Agios Pharmaceuticals' Board of Directors, effective February 28, 2025, but will remain as a strategic advisor.

Agios Pharmaceuticals outlines its anticipated 2025 milestones, including regulatory decisions for PYRUKYND in thalassemia and topline results from the Phase 3 RISE UP study in sickle cell disease.

The FDA has approved an update to the prescribing information for Agios Pharmaceuticals' PYRUKYND, adding warnings about liver injury observed in patients with another condition.

Agios Pharmaceuticals announced positive third-quarter 2024 results, highlighted by a $1.1 billion payment from Royalty Pharma and Servier, and advancements in their clinical pipeline.

Agios Pharmaceuticals reported positive topline data from multiple clinical trials, including a significant royalty agreement, and second quarter 2024 financial results.

Agios Pharmaceuticals held its annual meeting on June 20, 2024, where stockholders elected four Class II directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent auditor.

Agios Pharmaceuticals has agreed to sell its royalty rights for vorasidenib to Royalty Pharma for $905 million, with potential for additional payments based on sales performance.

Agios Pharmaceuticals announced its first quarter 2024 financial results, highlighted by $8.2 million in PYRUKYND revenue and progress in its clinical pipeline for rare diseases.

Agios Pharmaceuticals announced positive results from a Phase 3 study of Mitapivat and reported full year 2023 financial results, highlighting progress in their rare disease pipeline.